-+ 0.00%
-+ 0.00%
-+ 0.00%

Taysha Gene Therapies highlights Phase 1/2 REVEAL trial data for TSHA-102 in Rett syndrome at Child Neurology Society meeting

PUBT·10/01/2026 12:02:24
Listen to the news
Taysha Gene Therapies highlights Phase 1/2 REVEAL trial data for TSHA-102 in Rett syndrome at Child Neurology Society meeting
  • Taysha Gene Therapies flagged new encore presentations on TSHA-102 for Rett syndrome at the Child Neurology Society meeting on Oct. 14-17, 2026.
  • Clinical findings were already presented at the 2026 International Rett Syndrome Foundation scientific meeting.
  • Disclosed results point to functional improvements across multiple domains in both pediatric and older patients, alongside an acceptable safety profile.
  • Updates draw from the REVEAL Part A Phase 1/2 trial, positioning TSHA-102 as the company’s lead CNS gene therapy program.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Taysha Gene Therapies Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010800PRIMZONEFULLFEED9837334) on October 01, 2026, and is solely responsible for the information contained therein.